Key result
Dexmedetomidine as an adjuvant to epidural bupivacaine resulted in earlier onset of sensory blockade and longer duration of analgesia compared to fentanyl (P < 0.001).
Why the study?
Does epidural dexmedetomidine improve sensory blockade and analgesia duration compared to fentanyl when added to bupivacaine in patients undergoing lower limb surgeries?
RCT (n=60)
Randomized
Does epidural dexmedetomidine improve sensory blockade and analgesia duration compared to fentanyl when added to bupivacaine in patients undergoing lower limb surgeries?
p-value: p=<0.001
Dexmedetomidine is a superior adjuvant to epidural bupivacaine compared to fentanyl, offering faster onset and longer duration of analgesia for lower limb surgeries.
No takes yet. Share an insight, caveat, or question.
Supports preferring dexmedetomidine over fentanyl as epidural adjuvant in lower limb surgery; extends evidence for alpha-2 agonists in regional anesthesia.
Paul et al. (2017) conducted an RCT in Lower limb surgery (n=60). Dexmedetomidine vs. 100 μg fentanyl added to 38 ml of 0.25% bupivacaine was evaluated on Onset of sensory blockade and time to attain maximum sensory level (p=<0.001). Dexmedetomidine as an adjuvant to epidural bupivacaine resulted in earlier onset of sensory blockade and longer duration of analgesia compared to fentanyl (P < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: